Disease · MONDO_0019562

localized scleroderma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. localized scleroderma. Diseases, record MONDO_0019562. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019562

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: localized scleroderma; Open Targets
Open Targets ID: MONDO_0019562; Open Targets
Other names: Scleroderma, Localized, circumscribed scleroderma, localised fibrosing scleroderma, localised scleroderma, localised scleroderma (disorder) [ambiguous], localized fibrosing scleroderma, localized morphoea, localized scleroderma (disorder) [ambiguous], morphea, scleroderma, localised; Open Targets
Disease Ontology: DOID:8472; Disease Ontology
MeSH: D012594; MeSH
NCI Thesaurus: C72069; NCI Thesaurus
Orphanet: ORPHA:90289; Orphanet
Highest stage of its drugs: Phase 3, for 1 of its 6 drugs, from ClinicalTrials.gov; Open Targets

Drugs6

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
IMIQUIMOD	CHEMBL1282	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
CRISABOROLE	CHEMBL484785	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DUPILUMAB	CHEMBL2108675	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
SARILUMAB	CHEMBL2108730	Antibody	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
VELEDIMEX	CHEMBL3039523	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
CALCIPOTRIENE	CHEMBL1200666	Small molecule	Early phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets8

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
IL4R	Interleukin-4 receptor subunit alpha	1	Interleukin-4 receptor subunit alpha antagonist	Phase 2	https://conductscience.org/library/genes/3566	Drugs and targets
IL6R	Interleukin-6 receptor subunit alpha	1	Interleukin-6 receptor alpha subunit antagonist	Phase 1/2	https://conductscience.org/library/genes/3570	Drugs and targets
PDE4A	Phosphodiesterase 4	1	Phosphodiesterase 4 inhibitor	Phase 2	https://conductscience.org/library/genes/5141	Drugs and targets
PDE4B	Phosphodiesterase 4	1	Phosphodiesterase 4 inhibitor	Phase 2	https://conductscience.org/library/genes/5142	Drugs and targets
PDE4C	Phosphodiesterase 4	1	Phosphodiesterase 4 inhibitor	Phase 2	https://conductscience.org/library/genes/5143	Drugs and targets
PDE4D	Phosphodiesterase 4	1	Phosphodiesterase 4 inhibitor	Phase 2	https://conductscience.org/library/genes/5144	Drugs and targets
TLR7	Toll-like receptor 7	1	Toll-like receptor 7 agonist	Phase 3	https://conductscience.org/library/genes/51284	Drugs and targets
VDR	Vitamin D3 receptor	1	Vitamin D receptor agonist	Early phase 1	https://conductscience.org/library/genes/7421	Drugs and targets

Trials6

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03351114	Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea	Phase 2	8	2021-04-01	Morphea	CRISABOROLE	Its record names the disease	ClinicalTrials.gov
NCT02411643	Molecular Effects of Topical Calcipotriene on Morphea	Early phase 1	2	2018-09-13	Morphea, Localized Scleroderma	CALCIPOTRIENE	Its record names the disease	ClinicalTrials.gov
NCT03740724	A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)	Phase 1/2	1	2022-06-24	Morphea, Scleroderma, Localized, Scleroderma	VELEDIMEX	Its record names the disease	ClinicalTrials.gov
NCT04200755	Clinical Trial to Evaluate Efficacy and Safety of Dupilumab in Localized Scleroderma	Phase 2	45		Localized Scleroderma	DUPILUMAB	Its record names the disease	ClinicalTrials.gov
NCT00230373	Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study	Phase 3	0		Morphea	IMIQUIMOD	Its record names the disease	ClinicalTrials.gov
NCT03679845	Study to Assess Sarilumab in Halting Progression of Morphea	Phase 1/2	0		Morphea, Plaque Form	SARILUMAB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
42957460	DERIVED	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0019562

GET https://conductscience.org/api/diseases/v1/MONDO_0019562/drugs

API reference For AI assistants